Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 7912-7918

  Xing, T J ^a   Jiang, D F ^a   Huang, J X ^a   Xu, Z L ^a  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

Author keywords

Chronic hepatitis B; Hepatocellular carcinoma; MiR 122; MiR 29

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA 122; MICRORNA 29; VIRUS DNA; ALANINE AMINOTRANSFERASE; MICRORNA; MIRN122 MICRORNA, HUMAN; MIRN29 MICRORNA, HUMAN; PRIMER DNA;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE ANALYSIS; GENE SEQUENCE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPLICATION; GENETICS; HEPATITIS B VIRUS; LIVER NEOPLASMS; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PATHOLOGY;

HEPATITIS B VIRUS;

ALANINE TRANSAMINASE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA PRIMERS; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84907855230     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.September.29.4     Document Type: Article

References (16)

1. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Chen X, Ba Y, Ma L, Cai X, et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18: 997-1006.
3. Chinese Liver Disease Association (2011). Chinese Liver Disease Association and Chinese Medical Association Infectious Disease Branch. Chronic Hepatitis B Prevention Guide (2010 edn.). Chin. J. Hepatol. 19: 13-24.
4. Dykxhoorn DM and Lieberman J (2005). The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 56: 401-423.
5. Ganem D and Prince AM (2004). Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350: 1118-1129.
6. Lewis AP and Jopling CL (2010). Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 38: 1553-1557.
7. Li LM, Hu ZB, Zhou ZX, Chen X, et al. (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70: 9798-9807.
8. Lu FM and Zhuang H (2009). Management of hepatitis B in China. Chin. Med. J. 122: 3-4.
9. Qi P, Cheng SQ, Wang H, Li N, et al. (2011). Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 6: e28486.
10. Roderburg C, Trautwein C and Luedde T (2011). MicroRNA-199a/b-3p: a new star in the liver microcosmos. Hepatology 54: 729-731.
11. Venugopal SK, Jiang J, Kim TH, Li Y, et al. (2010). Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 298: G101-G106.
12. Waidmann O, Bihrer V, Pleli T, Farnik H, et al. (2012). Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J. Viral Hepat. 19: e58-e65.
13. Wong GL, Wong VW, Tan GM, Ip KI, et al. (2008). Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 28: 79-87.
14. Xu J, Wu C, Che X, Wang L, et al. (2011). Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 50: 136-142.
15. Zhang Y, Jia Y, Zheng R, Guo Y, et al. (2010). Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 56: 1830-1838.
16. Zhou J, Yu L, Gao X, Hu J, et al. (2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 29: 4781-4788.